216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

ARGX

550.4

+1.93%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

ARGX

550.4

+1.93%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

ARGX

550.4

+1.93%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

ARGX

550.4

+1.93%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

ARGX

550.4

+1.93%↑

Home・Listă Acțiuni・Sanofi SA

Sanofi SA

Închisă

Sector Sănătate

98.64 1.9

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

98.58

Maxim

98.85

Indicatori cheie
By Trading Economics
Venit	1.7B 2.8B
Vânzări	2.1B 13B
P/E Medie Sector	30.62 104.138
EPS	2.86
Marjă de profit	20.945
EBITDA	2.2B 4.2B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+13.82 upside

Dividende
By Dow Jones
Următoarele câștiguri	30 ian. 2025

Statistici piață
By TradingEconomics
Capitalizare de piață	123B
Deschiderea anterioară	96.74
Închiderea anterioară	98.64

Sentimentul știrilor

By Acuity

61%

39%

322 / 389 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

98.41 / 99.5 Suport & Rezistență

Sanofi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 oct. 2024, 10:07 UTC

Câștiguri

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 oct. 2024, 06:37 UTC

Câștiguri

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

28 oct. 2024, 16:07 UTC

Achiziții, Fuziuni, Preluări

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct. 2024, 05:44 UTC

Câștiguri

Sanofi Profit, Sales Beat Estimates

29 oct. 2024, 13:16 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 oct. 2024, 07:02 UTC

Market Talk

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 oct. 2024, 05:52 UTC

Câștiguri

Santander Backs 2024 View

29 oct. 2024, 05:52 UTC

Câștiguri

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 oct. 2024, 05:51 UTC

Câștiguri

Santander Confident on Delivering on Targets

29 oct. 2024, 05:50 UTC

Câștiguri

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct. 2024, 05:50 UTC

Câștiguri

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct. 2024, 05:49 UTC

Câștiguri

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 oct. 2024, 05:49 UTC

Câștiguri

Santander 3Q Net Interest Income EUR11.225B

29 oct. 2024, 05:48 UTC

Câștiguri

Analysts Saw Santander 3Q Net Loan Loss Provisions EUR3.17B

29 oct. 2024, 05:48 UTC

Câștiguri

Santander 3Q Net Loan Loss Provisions EUR2.98B

29 oct. 2024, 05:48 UTC

Câștiguri

Analysts Saw Santander 3Q Net Pft EUR3.17B

29 oct. 2024, 05:48 UTC

Câștiguri

Santander 3Q Net Pft EUR3.25B

29 oct. 2024, 05:48 UTC

Câștiguri

Santander 3Q Rev EUR15.135B

29 oct. 2024, 05:48 UTC

Câștiguri

Analysts Saw Santander 3Q Rev EUR15.31B

28 oct. 2024, 08:18 UTC

Market Talk

Banks' Risks From U.K. Motor Finance Probe Rise -- Market Talk

25 oct. 2024, 20:25 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 13:12 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 07:00 UTC

Market Talk

Câștiguri

Achiziții, Fuziuni, Preluări

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Adj EPS EUR2.86

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q FCF EUR3.33B

25 oct. 2024, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Business Net Profit EUR3.59B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Sales EUR13.44B

25 oct. 2024, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Business Operating Profit EUR4.61B

Comparație

Modificare preț

Sanofi SA Așteptări

Obiectiv de preț

By TipRanks

13.82% sus

Prognoză pe 12 luni

Medie 112.335 EUR 13.82%

Maxim 130 EUR

Minim 90 EUR

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 13 analiști care au acordat evaluări ale acțiunilor Sanofi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

98.41 / 99.5Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

322 / 389 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.